Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma

Cancer Letters

Volumn 357, Issue 2, 2015, Pages 468-475

  Zheng, Bing ^a   Mao, Jia Hui ^b   Qian, Lin ^a   Zhu, Hua ^a   Gu, Dong hua ^a   Pan, Xiao dong ^a   Yi, Fang ^c   Ji, Dong mei ^d  

^a NANTONG UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

^c FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Autophagy; AZD 2014; MTOR; Renal cell carcinoma; Sensitization and hypoxia inducible factor

Indexed keywords

3 METHYLADENINE; AUTOPHAGY PROTEIN 5; AZD 2014; BECLIN 1; CYCLIN D1; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN P62; RAPAMYCIN; SMALL INTERFERING RNA; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG EFFECTS; GENETICS; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AUTOPHAGY; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLIN D1; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MICE, NUDE; MORPHOLINES; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920747249     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.012     Document Type: Article

References (42)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Amato R.J. Chemotherapy for renal cell carcinoma. Semin. Oncol 2000, 27:177-186.
3. Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol 2010, 58:398-406.
4. Husseinzadeh H.D., Garcia J.A. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr. Clin. Pharmacol 2011, 6:214-221.
5. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
6. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
7. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
8. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med 2007, 356:2271-2281.
9. Pantuck A.J., Seligson D.B., Klatte T., Yu H., Leppert J.T., Moore L., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
10. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
11. Vilar E., Perez-Garcia J., Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. Cancer Ther 2011, 10:395-403.
12. Huo H.Z., Zhou Z.Y., Wang B., Qin J., Liu W.Y., Gu Y. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem. Biophys. Res. Commun 2014, 443:406-412.
13. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res 2007, 13:7271-7279.
14. Bialik S., Kimchi A. Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. Adv. Exp. Med. Biol 2008, 615:177-200.
15. Gozuacik D., Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004, 23:2891-2906.
16. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994, 45:48-57.
17. Zhen Y.F., Wang G.D., Zhu L.Q., Tan S.P., Zhang F.Y., Zhou X.Z., et al. P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone-induced death of osteoblasts. J. Cell. Physiol 2014, 229:1475-1483.
18. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11:859-871.
19. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
20. Efeyan A., Sabatini D.M. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol 2010, 22:169-176.
21. Minardi D., Lucarini G., Filosa A., Milanese G., Zizzi A., Di Primio R., et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int. J. Immunopathol. Pharmacol 2008, 21:447-455.
22. Di Cristofano C., Minervini A., Menicagli M., Salinitri G., Bertacca G., Pefanis G., et al. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am. J. Surg. Pathol 2007, 31:1875-1881.
23. Patel P.H., Chadalavada R.S., Chaganti R.S., Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin. Cancer Res 2006, 12:7215-7220.
24. Wiesener M.S., Munchenhagen P.M., Berger I., Morgan N.V., Roigas J., Schwiertz A., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001, 61:5215-5222.
25. Bindra R.S., Vasselli J.R., Stearman R., Linehan W.M., Klausner R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002, 62:3014-3019.
26. Hedberg Y., Ljungberg B., Roos G., Landberg G. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br. J. Cancer 2003, 88:1417-1423.
27. Hedberg Y., Davoodi E., Roos G., Ljungberg B., Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int. J. Cancer 1999, 84:268-272.
28. Chen X.G., Liu F., Song X.F., Wang Z.H., Dong Z.Q., Hu Z.Q., et al. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol. Carcinog 2010, 49:603-610.
29. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest 2008, 118:3065-3074.
30. Goudar R.K., Shi Q., Hjelmeland M.D., Keir S.T., McLendon R.E., Wikstrand C.J., et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther 2005, 4:101-112.
31. Hahn M., Li W., Yu C., Rahmani M., Dent P., Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol. Cancer Ther 2005, 4:457-470.
32. Shoji K., Oda K., Kashiyama T., Ikeda Y., Nakagawa S., Sone K., et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS ONE 2012, 7:e37431.
33. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol 2004, 22:4991-5004.
34. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003, 1:E83.
35. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1:237-246.
36. Toschi A., Lee E., Gadir N., Ohh M., Foster D.A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem 2008, 283:34495-34499.
37. Cho D.C., Cohen M.B., Panka D.J., Collins M., Ghebremichael M., Atkins M.B., et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res 2010, 16:3628-3638.
38. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol 2011, 13:132-141.
39. Jung C.H., Jun C.B., Ro S.H., Kim Y.M., Otto N.M., Cao J., et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 2009, 20:1992-2003.
40. Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007, 6:458-471.
41. Chen S., Han Q., Wang X., Yang M., Zhang Z., Li P., et al. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway. Cell Death Dis 2013, 4:e842.
42. Mizushima N., Yamamoto A., Hatano M., Kobayashi Y., Kabeya Y., Suzuki K., et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J. Cell Biol 2001, 152:657-668.